首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
【24h】

Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.

机译:半剂量ACEI + ARB联合利尿剂的滴定比联合ACEI + ARB联合利尿剂的减少蛋白尿更好。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Residual proteinuria is a strong modifiable risk factor for renal failure progression. We previously showed that the antiproteinuric effect of combined half doses of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) is increased by raising diuretic dosage. Methods. We tested whether uptitration of loop diuretics on top of combined half doses of ACEI and ARB would better decrease proteinuria than uptitration to combined full doses of ACEI and ARB in a randomized, crossover, three periods of 6-week controlled study. Eighteen patients with stable proteinuria over 1 g/day with combined ramipril at 5 mg/day and valsartan at 80 mg/day in addition to conventional antihypertensive treatments were randomized to receive combined ramipril at 5 mg/day and valsartan at 80 mg/day, or combined ramipril at 10 mg/day and valsartan at 160 mg/day, or combined ramipril at 5 mg/day, valsartan at 80 mg/day and increased furosemide dosage in random order. The primary end point was the mean urinary protein/creatinine ratio in two 24-hour urine collections at the end of the three treatment periods. Secondary end points included mean 24-hour proteinuria, home systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP) and estimated glomerular filtration rate (eGFR) levels. RESULTS: The geometric mean urinary protein/creatinine ratio was lower with combined ramipril at 5 mg/day, valsartan at 80 mg/day and increased furosemide dosage compared to combined ramipril at 5 mg/day and valsartan at 80 mg/day, but also to combined ramipril at 10 mg/day and valsartan at 160 mg/day. These differences remained significant after adjustment for SBP, DBP or MAP and 24-hour natriuresis but not after adjustment on eGFR. Diuretic dosage uptitration did not increase the number of home systolic blood pressure measurements below 100 mmHg, but led to a statistically significant increase in the number of symptomatic hypotension episodes. CONCLUSIONS: A cautious uptitration of loop diuretic dosage in addition to combined half doses of ACEI and ARB better decrease proteinuria in patients with CKD and high residual proteinuria than uptitration to full dose of combined ACEI and ARB. This antiproteinuric effect of diuretics was partly explained by an eGFR decrease, suggesting the contribution of haemodynamic modifications, whose safety on the long term still need to be addressed.
机译:背景:残余蛋白尿是肾衰竭进展的重要可改变危险因素。我们以前表明,通过增加利尿剂的剂量,联合使用半剂量血管紧张素转换酶抑制剂(ACEI)和血管紧张素受体阻滞剂(ARB)的抗蛋白尿作用。方法。我们在一项随机,交叉,三期为期6周的对照研究中,测试了在联合使用半剂量的ACEI和ARB的基础上增加环loop利尿剂的剂量是否比在联合使用的全剂量的ACEI和ARB的情况下提高了蛋白尿水平。除常规降压治疗外,将18名稳定蛋白尿超过1克/天,雷米普利5毫克/天和缬沙坦80毫克/天的患者随机分配至接受5毫克/天的雷米普利和80毫克/天的缬沙坦联合治疗,或雷米普利10毫克/天,缬沙坦160毫克/天,雷米普利5毫克/天,缬沙坦80毫克/天的联合用药和呋塞米剂量的随机服用。主要终点是三个治疗期结束时两个24小时尿液收集中的平均尿蛋白/肌酐比值。次要终点包括平均24小时蛋白尿,原始收缩压(SBP),舒张压(DBP),平均动脉压(MAP)和估计的肾小球滤过率(eGFR)水平。结果:与雷米普利联合5 mg /天和缬沙坦80 mg /天相比,雷米普利5 mg /天,缬沙坦80 mg /天和尿嘧啶胺的几何平均尿蛋白/肌酐比较低;合并雷米普利10毫克/天和缬沙坦160毫克/天。调整SBP,DBP或MAP以及24小时利尿后,这些差异仍然很明显,但调整eGFR后则不存在。利尿剂剂量的增加并不会增加低于100 mmHg的家庭收缩压测量值,但会导致有症状的低血压发作次数出现统计学上的显着增加。结论:谨慎地增加loop利尿剂的剂量以及联合使用半剂量的ACEI和ARB可以更好地降低CKD和高残留蛋白尿的患者的蛋白尿,而不是增加至完全剂量的ACEI和ARB的联合使用。利尿剂的这种抗蛋白尿作用部分地由eGFR降低解释,表明血液动力学修饰的作用,从长远来看其安全性仍需解决。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号